Τόμος 24 (2010) – Τεύχος 2 – Άρθρο 27 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 2 – Article 27 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Dpt of Medical Oncology, University General Hospital, Heraklion, Crete, Greece

            2. Carney D.: Lung Cancer-Time. To Move On From Chemotherapy. N. Engl. J. Med. 346: 126-128 (2002)

            3. Franklin W., Veve R., Hirsch F., Helfrich B., Bunn P., Jr.: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 29(1 Suppl 4): 3-14 (2002)

            4. Sedlacek H.: Kinase Inhibitors In Cancer Therapy: A Look Ahead. Drugs 59: 435-76 (2000)

            5. Ciardiello F., Tortora G.: Egfr Antagonists In Cancer Treatment. N. Engl. J. Med. 358: 1160-1174 (2008)

            6. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E. et al.: Saturn: A double-blind, randomized, phase iii study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced Nsclc. J. Clin. Oncol. 27(15s): Abstr 8001 (2009)

            7. Takeda K., Hida T., Sato T., Ando M., Seto T., Satouchi M., et al.: Randomized Phase Iii Trial Of Platinum-Doublet Chemotherapy Followed By Gefitinib Compared With Continued Platinum-Doublet Chemotherapy In Japanese Patients With Advanced Non-Small-Cell Lung Cancer: Results Of A West Japan Thoracic Oncology Group Trial (Wjtog0203). J. Clin. Oncol. 28: 753-760 (2010)

            8. Thatcher N., Chang A., Parikh P., Rodrigues Pj, Ciuleanu T., Von P., et al.: Gefitinib Plus Best Supportive Care In Previously Treated Patients With Refractory Advanced Non-Small-Cell Lung Cancer: Results From A Randomised, Placebo-Controlled, Multicentre Study (Iressa Survival Evaluation In Lung Cancer). Lancet 366: 1527-1537 (2005)

            9. Shepherd F., Rodrigues P., Ciuleanu T., Tan E., Hirsh V., Thongprasert S.. et al.: Erlotinib In Previously Treated Non-Small-Cell Lung Cancer. N. Engl. J. Med. 353: 123-132 (2005)

            10. Mok T., Wu Yl, Thongprasert S., Yang Ch., Chu Dt., Saijo N., et al.: Gefitinib Or Carboplatin-Paclitaxel In Pulmonary Adenocarcinoma. N. Engl J. Med. 361: 947-957 (2009)

            11. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al.: Gefitinib Versus Cisplatin Plus Docetaxel In Patients With Non-Small-Cell Lung Cancer Harbouring Mutations Of The Epidermal Growth Factor Receptor (Wjtog3405): An Open Label, Randomised Phase 3 Trial. Lancet Oncol. 11: 121-128 (2010)

            12. Kim E., Hirsh V., Mok T., Socinski M., Gervais R., Wu Yl, et al.: Gefitinib Versus Docetaxel In Previously Treated Non-Small-Cell Lung Cancer (Interest): A Randomised Phase Iii Trial. Lancet 372(9652): 1809-1818 (2008)

            13. Pirker R., Szczesna A., Von Pawel J., Krzakowski M., Ramlau R., Park K., et al.: Flex: A Randomized, Multicenter, Phase IΙΙ Study Of Cetuximab In Combination With Cisplatin/Vinorelbine (Cv) Versus Cv Alone In The First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (Nsclc). Proc. Am. Soc. Clin. Oncol. 26(20): Abstr 3 (2008)

            14. Gatzemeier U., Vonpawel J., Vynnchenko I., Zatloukal P., Demarinis F., O’byrne K., et al.: Cetuximab In Combination With Platinum-Based Chemotherapy Improves Survival Versus Chemotherapy Alone In The 1^st-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (Nsclc). Multidiciplinary Symposium In Thoracic Oncology Chicago, November 2008 2008

            15. Langer C.: Will Flex Allow Us Flexibility In The Therapy Of Advanced Non-Small-Cell Lung Cancer? Insights From The 2008 American Society Of Clinical Oncology Meeting. Clin. Lung Cancer 9: 249-251 (2008)

            16. Lynch T., Patel R., Dreisbach L., Mcleod M., Heim W., Hermann R., et al.: A Randomized Multicenter Phase Iii Study Of Cetuximab (Erbitux(R)) In Combination With Taxane/Carboplatin Versus Taxane/Carboplatin Alone As First-Line Treatment For Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (Nsclc): B3-03. J. Thorac. Oncol. 2(8): S340-S341 (2007)

            17. Pallis A., Serfass L., Dziadziusko R., Van Meerbeeck J., Fennell D., Lacombe D., et al.: Targeted Therapies In The Treatment Of Advanced/Metastatic Nsclc. Eur. J. Cancer 45: 2473-2487 (2009)

            18. Sandler A., Gray R., Perry M., Brahmer J., Schiller J., Dowlati A., et al.: Paclitaxel-Carboplatin Alone Or With Bevacizumab For Non-Small-Cell Lung Cancer. N. Engl. J. Med. 355: 2542-2550 (2006)

            19. Reck M., Von P., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al.: Phase Iii Trial Of Cisplatin Plus Gemcitabine With Either Placebo Or Bevacizumab As First-Line Therapy For Nonsquamous Non-Small-Cell Lung Cancer: Avail. J. Clin. Oncol. 27: 1227-1234 (2009)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr